Metformin Efficacy on Proliferation Indices of Tumoral Cells in NonDiabetic Patients with Invasive Breast Cancer Referring to the Cancer Institute of Iran

Background: Because of the decreasing effect of metformin on insulin resistance, it has been suggested as an antiobesity and anticancer drug. So, we aimed to study the effect of metformin therapy on tumor cell proliferation in nondiabetic breast cancer patients. Methods: We conducted a prospective clinical trial and studied the effect of metformin therapy on the level of Ki67 as a measure of tumor cell proliferation. Our primary endpoint was to evaluate the changes in Ki67. The intervention group consisted of 25 nondiabetic breast cancer patients with no indication for neoadjuvant chemo therapy. They were followed up from the time of biopsy to operation. Metformin (1500 mg/day) was prescribed in the intervention group from the date of diagnosis until the surgery (2.8 weeks). Controls were 20 early breast cancer patients who had been followed up with no prescription from biopsy until operation. Results: We could not find any statistically significant difference between the two groups regarding baseline clinical or tumor characteristics such as age, stage, grade, estrogen receptor, HER2 status or time, and type of surgery. However, the immuno histochemistry (IHS) study showed a decrease in median Ki67 from 35.14 to 29.6 in the intervention group (Pvalue= 0.02). While an increase from 24.5 to 30.6 was detected in the control group (Pvalue= 0.02). Both of these changes were statistically significant. Although mild gastrointestinal symptoms were seen in approximately 50% of cases, generally, patients tolerated metformin well. There was a correlation between the score of HOMA, a metabolic factor, and the changes in KI67. Conclusion: Metformin prescription in a short period of time between biopsy and definitive surgery leads to the inhibition of breast cancer cell growth. We found a relationship between metformin antiproliferative effect and glucose and insulin metabolism.